Leukemia, Acute Myeloid disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LKM061 MIFTS: 80	Leukemia, Acute Myeloid Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Name: Leukemia, Acute Myeloid ⁵⁷ ³⁸

Acute Myeloid Leukemia ³⁸ ¹² ⁷⁶ ⁵³ ⁷⁵ ³⁷ ²⁹ ⁶ ⁴³ ¹⁵

Leukemia, Acute Myelogenous ⁵⁷ ⁷⁵ ¹³ ⁴⁰

Leukemia, Acute Myeloid, Susceptibility to ⁵⁷ ²⁹ ⁶

Acute Undifferentiated Leukemia ⁵⁹ ⁵⁵ ⁷³

Acute Myeloblastic Leukemia ¹² ⁷⁶ ⁷⁵

Acute Myelogenous Leukemia ¹² ⁷⁶ ⁵³

Acute Biphenotypic Leukemia ⁵⁹ ⁷³

Leukemia, Myelocytic, Acute ¹² ⁷³

Acute Myelocytic Leukemia ⁷⁶ ⁷⁵

Leukemia, Myeloid, Acute ⁴⁴ ⁴⁰

Aml ⁵⁷ ⁷⁵

Acute Myeloid Leukaemia with Myelodysplasia-Related Features ⁵⁹

Acute Myeloid Leukemia, Minimal Differentiation, Fab M0 ⁵⁹

Leukemia, Acute Myeloid, Reduced Survival in, Somatic ⁵⁷

Acute Myeloid Leukemia with Cebpa Somatic Mutations ⁵⁹

Acute Myeloid Leukemia with Multilineage Dysplasia ⁵⁹

Myeloid Leukemia, Acute, M4/m4eo Subtype, Somatic ⁵⁷

Aml with Myelodysplasia-Related Features ⁵⁹

Pure Familial Acute Myeloid Leukemia ⁵⁹

Leukemia, Acute Myeloid, Somatic ⁵⁷

Aml with Cebpa Somatic Mutations ⁵⁹

Inherited Acute Myeloid Leukemia ⁵⁹

Acute Non-Lymphoblastic Leukemia ⁷⁵

Acute Myeloid Leukemia, Somatic ⁵⁷

Aml with Multilineage Dysplasia ⁵⁹

Acute Non-Lymphocytic Leukemia ⁷⁵

Aml - Acute Myeloid Leukemia ¹²

Bilineal Acute Leukemia ⁵⁹

Pure Familial Aml ⁵⁹

Inherited Aml ⁵⁹

Familial Aml ⁵⁹

Characteristics:

Orphanet epidemiological data:

⁵⁹

acute myeloid leukaemia with myelodysplasia-related features
Age of onset: Adult;

OMIM:

⁵⁷

Inheritance:
autosomal dominant

HPO:

³²

leukemia, acute myeloid:
Inheritance autosomal dominant inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³³ ³⁴

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Leukaemia of unspecified cell type

Acute leukaemia of unspecified cell type

Myeloid leukaemia

Acute myeloblastic leukaemia [AML]

Acute myeloid leukaemia with 11q23-abnormality

Acute myeloid leukaemia with multilineage dysplasia

Orphanet: ⁵⁹

Rare haematological diseases

External Ids:

OMIM ⁵⁷ 601626

Disease Ontology ¹² DOID:9119

ICD10 ³³ C92.0 C92.00 C92.6 more

ICD9CM ³⁵ 205.0

MeSH ⁴⁴ D015470

NCIt ⁵⁰ C27753 C3171

SNOMED-CT ⁶⁸ 154591002 17788007 277600006 more

Orphanet ⁵⁹ ORPHA319480 ORPHA319465 ORPHA86845 more

ICD10 via Orphanet ³⁴ C92.0 C92.8 C95.0

UMLS via Orphanet ⁷⁴ C1292773 C0023464 C0280141 more

MESH via Orphanet ⁴⁵ D015456

MedGen ⁴² C0023467 C3275959

KEGG ³⁷ H00003

SNOMED-CT via HPO ⁶⁹ 263681008

UMLS ⁷³ C0023467 C0280141

Sources

Summaries for Leukemia, Acute Myeloid

MedlinePlus : ⁴³ Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast. AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation. Symptoms of AML include: Fever Shortness of breath Easy bruising or bleeding Bleeding under the skin Weakness or feeling tired Weight loss or loss of appetite Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Acute Myeloid, also known as acute myeloid leukemia, is related to acute myeloblastic leukemia without maturation and acute myeloblastic leukemia with maturation, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, Acute Myeloid is CEBPA (CCAAT Enhancer Binding Protein Alpha), and among its related pathways/superpathways are Acute myeloid leukemia and Transcriptional misregulation in cancer. The drugs Leukine and Lynparza have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute myeloid leukemia and Reduced mammosphere formation

Disease Ontology : ¹² A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.

NIH Rare Diseases : ⁵³ Acute myeloid leukemia (AML) is a cancer that affects the blood and bone marrow. Conditions are generally called "acute" when they develop quickly and have an aggressive course. The signs and symptoms of AML vary but may include easy bruising; bone pain or tenderness; fatigue; fever; frequent nosebleeds; bleeding from the gums; shortness of breath; and/or weightloss. AML is one of the most common types of leukemia among adults and is rarely diagnosed in people under age 40. There are many potential causes of AML such as certain blood disorders, inheritedsyndromes, environmental exposures, and drug exposures; however, most people who develop AML have no identifiable risk factor. Treatment may include a combination of chemotherapy, radiation therapy, bone marrow transplant and/or other drug therapy.

UniProtKB/Swiss-Prot : ⁷⁵ Leukemia, acute myelogenous: A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.

Wikipedia : ⁷⁶ Acute myeloblastic leukemia is a form of myeloid leukemia affecting... more...

Description from OMIM: 601626

Sources

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid	Leukemia, Chronic Myeloid
Acute Myeloid Leukemia with T(9;11)(p22;q23)	Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 59)

#	Related Disease	Score	Top Affiliating Genes
1	acute myeloblastic leukemia without maturation	36.2	FLT3 NPM1
2	acute myeloblastic leukemia with maturation	36.1	FLT3 KIT NPM1
3	leukemia	35.2	CEBPA ETV6 FLT3 JAK2 KIT NPM1
4	acute promyelocytic leukemia	35.2	CEBPA FLT3 NPM1 NRAS RUNX1
5	platelet disorder, familial, with associated myeloid malignancy	35.1	ETV6 RUNX1
6	acute leukemia	34.7	CEBPA ETV6 FLT3 JAK2 KIT MLLT10
7	cytogenetically normal acute myeloid leukemia	34.3	CEBPA FLT3 IDH1 NPM1
8	myeloid leukemia	34.3	CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
9	myelodysplastic syndrome	33.0	CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
10	leukemia, acute lymphoblastic	32.0	ETV6 FLT3 PICALM RUNX1
11	lymphoblastic leukemia	31.8	ETV6 FLT3 JAK2 RUNX1
12	myeloid sarcoma	31.8	FLT3 KIT NPM1
13	acute non lymphoblastic leukemia	12.5
14	acute biphenotypic leukemia	12.4
15	hematologic cancer	12.1	ETV6 FLT3 GATA2 JAK2 KIT MLLT10
16	core binding factor acute myeloid leukemia	11.9	CEBPA FLT3 JAK2 KIT KRAS NRAS
17	aml with myelodysplasia-related features	11.9
18	leukemia, chronic myeloid	11.9	ETV6 FLT3 GATA2 JAK2 KIT NRAS
19	chronic myelomonocytic leukemia	11.9	DNMT3A ETV6 FLT3 JAK2 KIT RUNX1
20	juvenile myelomonocytic leukemia	11.8	DNMT3A FLT3 JAK2 KRAS NRAS RUNX1
21	bone marrow cancer	11.8	ETV6 FLT3 JAK2 KIT RUNX1
22	precursor t-cell acute lymphoblastic leukemia	11.7	ETV6 FLT3 MLLT10 NUP214 PICALM
23	wilms tumor 1	11.7	CEBPA FLT3 KRAS NPM1 TERT
24	acute myeloid leukemia with t(8;21)(q22;q22) translocation	11.7	CEBPA FLT3 KIT RUNX1
25	acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)	11.7	ETV6 FLT3 KIT RUNX1
26	lung cancer susceptibility 3	11.7	DNMT3A IDH1 KRAS NRAS TERT
27	cell type cancer	11.7	IDH1 KIT KRAS NRAS
28	acral lentiginous melanoma	11.6	KIT NRAS TERT
29	lymphoid leukemia	11.6	ETV6 FLT3 JAK2
30	vulvar melanoma	11.6	KIT NRAS TERT
31	undifferentiated pleomorphic sarcoma	11.6	IDH1 KIT KRAS
32	mucosal melanoma	11.6	KIT NRAS TERT
33	congenital mesoblastic nephroma	11.5	ETV6 KIT NRAS
34	myelofibrosis	11.5	FLT3 IDH1 JAK2 KIT
35	aleukemic leukemia cutis	11.5	FLT3 NPM1 RUNX1
36	8p11 myeloproliferative syndrome	11.5	FLT3 KIT RUNX1
37	aplastic anemia	11.5	FLT3 GATA2 NRAS TERT
38	leukemia, acute lymphoblastic 3	11.4	ETV6 FLT3 RUNX1
39	differentiated thyroid carcinoma	11.4	ETV6 KRAS NRAS
40	b-cell childhood acute lymphoblastic leukemia	11.4	ETV6 RUNX1
41	acute leukemia of ambiguous lineage	11.3
42	cholangiocarcinoma	11.3	IDH1 KIT KRAS TERT
43	schimmelpenning-feuerstein-mims syndrome	11.3	KRAS NRAS
44	ovarian melanoma	11.3	KIT NRAS
45	cellular congenital mesoblastic nephroma	11.2	ETV6 NRAS
46	erythroleukemia, familial	11.2
47	megakaryocytic leukemia	11.1
48	medulloblastoma	11.1
49	neutrophilia, hereditary	11.1	FLT3 JAK2
50	aggressive digital papillary adenocarcinoma	11.0	KIT KRAS

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:

Sources

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Symptoms via clinical synopsis from OMIM:

⁵⁷

Heme:
familial acute myelogenous leukemia (aml)

Misc:
evidence of anticipation
mean onset age 57 years, 32 years and 13 years in successive generations

Clinical features from OMIM:

601626

Human phenotypes related to Leukemia, Acute Myeloid:

³²

#	Description	HPO Frequency	HPO Source Accession
1	acute myeloid leukemia ³²		HP:0004808

UMLS symptoms related to Leukemia, Acute Myeloid:

angina pectoris, chest pain, edema

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.17	CEBPA DNMT3A ETV6 KRAS NRAS NUP214

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

⁴⁶ (show all 17)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.46	ETV6 FLT3 GATA2 JAK2 KIT KRAS
2	homeostasis/metabolism	MP:0005376	10.4	CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
3	hematopoietic system	MP:0005397	10.39	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
4	growth/size/body region	MP:0005378	10.37	CEBPA DNMT3A ETV6 FLT3 GATA2 IDH1
5	mortality/aging	MP:0010768	10.36	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
6	immune system	MP:0005387	10.32	DNMT3A ETV6 FLT3 IDH1 JAK2 KIT
7	endocrine/exocrine gland	MP:0005379	10.31	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
8	embryo	MP:0005380	10.29	KRAS NPM1 NRAS NUP214 PICALM RUNX1
9	cardiovascular system	MP:0005385	10.22	KRAS NPM1 NRAS RUNX1 CEBPA CHIC2
10	integument	MP:0010771	10.16	CEBPA CHIC2 ETV6 JAK2 KIT KRAS
11	liver/biliary system	MP:0005370	10.09	RUNX1 CEBPA GATA2 JAK2 KIT KRAS
12	neoplasm	MP:0002006	10.07	CEBPA ETV6 FLT3 JAK2 KIT KRAS
13	normal	MP:0002873	9.91	TERT CEBPA ETV6 GATA2 JAK2 KIT
14	no phenotypic analysis	MP:0003012	9.87	CEBPA ETV6 FLT3 KIT KRAS NRAS
15	reproductive system	MP:0005389	9.61	JAK2 KIT KRAS LPP TERT CEBPA
16	pigmentation	MP:0001186	9.55	CHIC2 KIT KRAS NRAS PICALM
17	skeleton	MP:0005390	9.32	FLT3 IDH1 JAK2 KIT KRAS NRAS

Sources

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Leukine ¹⁸	SARGRAMOSTIM	Immunex	on November 24, 1995/ November 1996
FDA Label: Leukine Disease/s that Drug Treats:transplantation/ replenishment of white blood cells, fungal infections Indications and Usage: ¹⁸ DrugBank Targets: ¹⁶ 1. Granulocyte-macrophage colony-stimulating factor receptor subunit alpha;2. Interleukin-3 receptor subunit alpha;3. Cytokine receptor common subunit beta;4. Syndecan-2;5. Bone marrow proteoglycan Mechanism of Action: ¹⁸ Target: - Action: - FDA: -
2	Lynparza ¹⁸ ⁴⁹	OLAPARIB	AstraZeneca	December 2014
FDA Label: Lynparza Disease/s that Drug Treats:previously treated BRCA mutated advanced ovarian cancer Indications and Usage: ¹⁸ Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated asmonotherapy in patients with deleterious or suspected deleterious germlineBRCA mutated (as detected by an FDA-approved test) advanced ovariancancer who have been treated with three or more prior lines of chemotherapy.(1.1)The indication is approved under accelerated approval based on objectiveresponse rate and duration of response. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1 1, 14) DrugBank Targets: ¹⁶ 1. Poly [ADP-ribose] polymerase 1;2. Poly [ADP-ribose] polymerase 2;3. Poly [ADP-ribose] polymerase 3 Mechanism of Action: ¹⁸ Target: poly (ADP-ribose) polymerase (PARP) Action: inhibitor FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNArepair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mousexenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increasedcytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor modelswith deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition ofPARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasisand cell death.
3	Mylotarg ¹⁸ ⁴⁹	GEMTUZUMAB OZOGAMICIN	Wyeth	May 2000
FDA Label: Mylotarg Disease/s that Drug Treats:Acute Myeloid Leukemia (AML) Indications and Usage: ¹⁸ Mylotarg is indicated for the treatment of patients with CD33 positive acute myeloid leukemia infirst relapse who are 60 years of age or older and who are not considered candidates for othercytotoxic chemotherapy. The safety and efficacy of Mylotarg in patients with poor performancestatus and organ dysfunction has not been established.The effectiveness of Mylotarg is based on OR rates (see CLINICAL STUDIES section). Thereare no controlled trials demonstrating a clinical benefit, such as improvement in disease-relatedsymptoms or increased survival, compared to any other treatment. DrugBank Targets: ¹⁶ 1. Myeloid cell surface antigen CD33;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c Mechanism of Action: ¹⁸ Target: CD33 antigen expressed byhematopoietic cells Action: binds to form complex that then causes a break in the DNA double strand FDA: Mylotarg is directed against the CD33 antigen expressed byhematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33antigen results in the formation of a complex that is internalized. Upon internalization, thecalicheamicin derivative is released inside the lysosomes of the myeloid cell. The releasedcalicheamicin derivative binds to DNA in the minor groove resulting in DNA double strandbreaks and cell death.Gemtuzumab ozogamicin is cytotoxic to the CD33 positive HL-60 human leukemia cell line.Gemtuzumab ozogamicin produces significant inhibition of colony formation in cultures of adultleukemic bone marrow cells. The cytotoxic effect on normal myeloid precursors leads tosubstantial myelosuppression, but this is reversible because pluripotent hematopoietic stem cellsare spared. In preclinical animal studies, gemtuzumab ozogamicin demonstrates antitumoreffects in the HL-60 human promyelocytic leukemia xenograft tumor in athymic mice.
4	Neupogen ¹⁸ ⁴⁹	FILGRASTIM	Amgen	Approval April 1998
FDA Label: Neupogen Disease/s that Drug Treats:slow white blood cell recovery following chemotherapy Indications and Usage: ¹⁸ NEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infectionâ as manifested by febrile neutropeniaâin patients with nonmyeloid malignancies receiving myelosuppressive anticancerdrugs associated with a significant incidence of severe neutropeniawith fever (1.1) Reduce the time to neutrophil recovery and the duration of fever, followinginduction or consolidation chemotherapy treatment of patients with acutemyeloid leukemia (AML) (1.2) Reduce the duration of neutropenia and neutropenia-related clinicalsequelaeâ e.g.â febrile neutropenia, in patients with nonmyeloidmalignancies undergoing myeloablative chemotherapy followed by bonemarrow transplantation (BMT) (1.3) Mobilize autologous hematopoietic progenitor cells into the peripheralblood for collection by leukapheresis (1.4) Reduce the incidence and duration of sequelae of severe neutropenia (e.g.âfeverâ infectionsâ oropharyngeal ulcers) in symptomatic patients withcongenital neutropeniaâ cyclic neutropeniaâ or idiopathic neutropenia (1.5) Increase survival in patients acutely exposed to myelosuppressive doses ofradiation (Hematopoietic Syndrome of Acute Radiation Syndrome) (1.6) DrugBank Targets: ¹⁶ 1. Granulocyte colony-stimulating factor receptor;2. Neutrophil elastase Mechanism of Action: ¹⁸ Target: hematopoietic cells Action: stimulates proliferation/ regulated production of neutophils FDA: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cellsurface receptors and stimulating proliferationâ differentiation commitmentâ and some end-cell functionalactivation.Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytesâfibroblasts, and endothelial cells. G-CSF regulates the production of neutrophils within the bone marrowand affects neutrophil progenitor proliferationâ differentiation, and selected end-cell functions (includingenhanced phagocytic abilityâ priming of the cellular metabolism associated with respiratory burstâantibody-dependent killing, and the increased expression of some cell surface antigens). G-CSF is notspecies-specific and has been shown to have minimal direct in vivo or in vitro effects on the production oractivity of hematopoietic cell types other than the neutrophil lineage.

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 643)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cytarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

147-94-4

6253

Idarubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

58957-92-9

42890

Fludarabine

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

21679-14-1, 75607-67-9

30751

Vidarabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

24356-66-9

32326 21704

Azacitidine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

320-67-2

9444

Decitabine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

2353-33-5

451668

Daunorubicin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

20830-81-3

30323

Mitoxantrone

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

65271-80-9

4212

Etoposide

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

33419-42-0

36462

Benzocaine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

1994-09-7, 94-09-7

2337

Lenograstim

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

135968-09-1

Prednisone

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1

53-03-2

5865

Topotecan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

119413-54-6, 123948-87-8

60700

Amsacrine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

51264-14-3

2179

Aldesleukin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

85898-30-2, 110942-02-4

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Thiotepa

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

52-24-4

5453

Lenalidomide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

191732-72-6

216326

Histamine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

75614-87-8, 51-45-6

774

Micafungin

Approved, Investigational

Phase 4,Phase 2

235114-32-6

3081921 477468

Posaconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

171228-49-2

147912

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Phase 1

51-61-6, 62-31-7

681

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

942 89594

tannic acid

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2

1406-16-2

Vitamin D3

Approved, Nutraceutical

Phase 4,Phase 2

67-97-0

6221 5280795

Ergocalciferol

Approved, Nutraceutical

Phase 4,Phase 2

50-14-6

5280793

Molgramostim

Investigational

Phase 4,Phase 3

99283-10-0

Aclarubicin

Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

57576-44-0

451415

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antiviral Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antineoplastic Agents, Phytogenic

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Etoposide phosphate

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Cyclosporins

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Gemtuzumab

Phase 4,Phase 2,Phase 3,Phase 1

topoisomerase I inhibitors

Phase 4,Phase 2,Phase 1

Analgesics, Non-Narcotic

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interleukin-2

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Neurotransmitter Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Antifungal Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2491)

#	Name	Status	NCT ID	Phase	Drugs
1	Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia	Unknown status	NCT02277847	Phase 4	Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2	AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy	Unknown status	NCT02024308	Phase 4	Fludarabine;Cytarabine
3	Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation	Unknown status	NCT01806116	Phase 4	decitabine
4	3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia	Unknown status	NCT01587430	Phase 4	high dose ARA-C;standard dose ARA-C
5	Efficacy of G-CSF-Priming in Elderly AML Patients	Unknown status	NCT00199147	Phase 4	Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
6	Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia	Unknown status	NCT01997372	Phase 4	ATG
7	Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）	Unknown status	NCT02218437	Phase 4	MSC+ATG
8	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)	Completed	NCT01041040	Phase 4	gemtuzumab
9	Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years	Completed	NCT00464217	Phase 4	ARA-C;Idarubicin;Leucomax
10	Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Completed	NCT00488709	Phase 4	Topotecan;Fludarabine;Cytarabine
11	Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia	Completed	NCT01819792	Phase 4
12	SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia	Completed	NCT00487448	Phase 4	Fludarabine;Cytarabine;G-CSF;Idarubicin
13	AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years	Completed	NCT00180102	Phase 4	Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
14	Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia	Completed	NCT01347996	Phase 4	histamine dihydrochloride and IL-2
15	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Completed	NCT01200355	Phase 4	micafungin;posaconazole
16	AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients	Completed	NCT00180115	Phase 4	Cytarabine Dosage
17	Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC	Completed	NCT00180167	Phase 4	randomization between two established Chemotherapies
18	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia	Completed	NCT00304447	Phase 4	Mylotarg
19	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)	Completed	NCT00686543	Phase 4	Posaconazole
20	Bone Marrow Transplantation in Treating Patients With Hematologic Cancer	Completed	NCT00003398	Phase 4	cyclophosphamide;thiotepa
21	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
22	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
23	Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients	Recruiting	NCT03150134	Phase 4	Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
24	Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML	Recruiting	NCT02926586	Phase 4	Fludarabine;Cytarabine
25	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT	Recruiting	NCT02027064	Phase 4	Interferon-alpha
26	Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients	Recruiting	NCT02267993	Phase 4	recombinant human thrombopoietin
27	Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections	Recruiting	NCT02805946	Phase 4	posaconazole
28	Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia	Recruiting	NCT02618109	Phase 4
29	Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)	Active, not recruiting	NCT03026842	Phase 4	Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
30	A Rollover Study to Provide Continued Treatment With Eltrombopag	Active, not recruiting	NCT01957176	Phase 4	ELT
31	King's Invasive Aspergillosis Study II	Not yet recruiting	NCT02875743	Phase 4	Posaconazole
32	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor	Not yet recruiting	NCT02933333	Phase 4
33	A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT	Not yet recruiting	NCT03176849	Phase 4
34	LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)	Terminated	NCT01198054	Phase 4	Lenalidomide
35	the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient	Unknown status	NCT01766375	Phase 3	Cyclosporin A,mycophenolate mofetil,Methotrexate
36	HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia	Unknown status	NCT01484171	Phase 3	idarubicin
37	A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia	Unknown status	NCT01303796	Phase 3	Sapacitabine and decitabine;Decitabine
38	Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia	Unknown status	NCT02244658	Phase 3	rhTPO
39	Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia	Unknown status	NCT02171117	Phase 3
40	Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients	Unknown status	NCT01633099	Phase 3	Decitabine
41	Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)	Unknown status	NCT01145846	Phase 3	Cytarabine plus Daunorubicin [Arm II (AD regimen)]
42	Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T	Unknown status	NCT00209833	Phase 2, Phase 3	Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
43	Randomised Prospective Comparison of the NMA Allograft and the Traditional Allograft in Acute Myeloid Leukaemia	Unknown status	NCT00224614	Phase 3
44	Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study	Unknown status	NCT00715637	Phase 3	Daunorubicin and Cytarabine;Amonafide and Cytarabine
45	Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia	Unknown status	NCT00002658	Phase 3	amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
46	Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	Unknown status	NCT00003602	Phase 3	cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
47	Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents	Unknown status	NCT00111345	Phase 2, Phase 3	Anthracyclines;liposomal daunorubicin;2-CDA;AI
48	Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia	Unknown status	NCT00006045	Phase 3	cytarabine;etoposide;mitoxantrone hydrochloride
49	Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia	Unknown status	NCT02072811	Phase 3	DAC;CLAG;Consolidation, I HAM cycle;II Consolidation HiDAraC;Consolidation, III HiDAraC cycle
50	Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia	Unknown status	NCT00002549	Phase 3	busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride

Search NIH Clinical Center for Leukemia, Acute Myeloid

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :

cyclophosphamide

etoposide

etoposide phosphate

idarubicin

idarubicin hydrochloride

mitoxantrone

mitoxantrone hydrochloride

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Leukemia, Acute Myeloid cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Leukemia, Acute Myeloid:

	Hemacord
	Hematopoietic stem cells for treatment of hematologic malignancies
	NiCord
	Peripheral blood stem cells for treatment of hematologic malignancies
	StemEx

Embryonic/Adult Cultured Cells Related to Leukemia, Acute Myeloid:

	Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD PMIDs: 9828244
	Bone marrow-derived hematopoietic stem cells
	Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
	Peripheral blood-derived hematopoietic stem cells (family)
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: leukemia, myeloid, acute

Sources

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

#	Genetic test	Affiliating Genes
1	Acute Myeloid Leukemia ²⁹	CEBPA DNMT3A KRAS
2	Leukemia, Acute Myeloid, Susceptibility to ²⁹

Sources

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

⁴¹

Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Monocytes

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Myeloid:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Common Myeloid Progenitor Cells	Affected by disease
2	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate

Sources

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

(show top 50) (show all 4771)

#	Title	Authors	Year
1	Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Adv</i>. 2017;2(4):444-453. ( 29618463 )		2018
2	High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )	Wang J....Jin J.	2018
3	Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )	Gurnari C....Voso M.T.	2018
4	Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. ( 29573577 )	Wang S....Chen B.	2018
5	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )	Devillier R....Mohty M.	2018
6	Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )	Van de Louw A....Claxton D.F.	2018
7	A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )	Li H....Gao S.	2018
8	Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. ( 29705537 )	Tan Y....Wang H.	2018
9	Editorial Comment to Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29869384 )	Kishida T.	2018
10	MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. ( 29976747 )	Seipel K....Pabst T.	2018
11	Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. ( 29168399 )	AasebA...Bruserud A.9.	2018
12	High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. ( 28836868 )	Si T....Zhou J.X.	2018
13	Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34a8_CD123a8_ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. ( 29439554 )	Schmidt J.R....Heidenreich F.	2018
14	Patient-reported outcomes in acute myeloid leukemia: Where are we now? ( 28888621 )	Buckley S.A....Lyman G.H.	2018
15	A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. ( 29892549 )	Hofmans M....Moors I.	2018
16	Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia. ( 29154208 )	Yang F....Zheng G.	2018
17	Regulation of Expression of CEBP Genes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor I+ in Human Acute Myeloid Leukemia Cell Lines. ( 29966306 )	Marchwicka A....Marcinkowska E.	2018
18	Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia. ( 28540755 )	Saini L....Sandhu I.	2018
19	Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. ( 29843224 )	Zahran A.M....Hetta H.F.	2018
20	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. ( 29247780 )	Shimoni A....Nagler A.	2018
21	The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia. ( 28646564 )	van Solinge T.S....Schuurhuis G.J.	2018
22	Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )	Li M....Yang X.	2018
23	Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. ( 29928481 )	Calmettes C....Dumas P.Y.	2018
24	Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. ( 29661468 )	Liu Y....Gu W.Y.	2018
25	Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )	Liu H....Liu B.	2018
26	Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). ( 29978286 )	Konuma T....Yano S.	2018
27	Acute Progressive Visual Loss in a Case of Acute Myeloid Leukemia: Challenges in the Utility of Molecular Tests in Early Diagnose of Cytomegalovirus Retinitis. ( 29560000 )	Amanati A....Zekavat O.R.	2018
28	Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience. ( 29200163 )	Hong K.T....Shin H.Y.	2018
29	Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. ( 29627222 )	Zhang T.J....Qian J.	2018
30	Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia. ( 29980537 )	Bernson E....Thoren F.B.	2018
31	Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). ( 28838276 )	Falantes J....Ramos F.	2018
32	Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )	Di Franco G....Morelli L.	2018
33	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. ( 29321554 )	Saygin C....Advani A.S.	2018
34	<i>NPM1</i> Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. ( 29129825 )	Kumar D....Saikia K.K.	2018
35	Initial therapy for acute myeloid leukemia in older patients: principles of care. ( 28573900 )	Bhatt V.R....Maness L.J.	2018
36	Nucleophosmin-1 regions associated with acute myeloid leukemia interact differently with lipid membranes. ( 29330024 )	De Santis A....Marasco D.	2018
37	CD16+NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. ( 29976748 )	Williams B.A....Keating A.	2018
38	A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. ( 29119643 )	Deangelo D.J....Ballen K.K.	2018
39	Acute external otitis as debut of acute myeloid leukemia - A case and review of the literature. ( 29447882 )	Slengerik-Hansen J....Ovesen T.	2018
40	NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no. ( 29866886 )	Griessinger E....Andreeff M.	2018
41	Protracted Clonal Trajectory of a <i>JAK2</i> V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. ( 29854499 )	Langabeer S.E....Murphy P.T.	2018
42	Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. ( 29981272 )	Gilleece M.H....Nagler A.	2018
43	Outcomes of measurable residual disease in pediatric acute myeloid leukemia pre- and post-hematopoietic stem cell transplant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. ( 29933069 )	Jacobsohn D.A....Pulsipher M.A.	2018
44	Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature. ( 29428448 )	Blakley M.P....Wiernik P.H.	2018
45	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. ( 29692343 )	Itzykson R....Preudhomme C.	2018
46	Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. ( 29097499 )	Medeiros B.C....Gale R.P.	2018
47	Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29752743 )	Inoue Y....Ukimura O.	2018
48	Identification of novel <i>MECOM</i> gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review. ( 29572239 )	Connelly J.A....Walkovich K.	2018
49	Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. ( 29449224 )	Mastaglio S....Ritchie D.	2018
50	Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. ( 29487059 )	Stone R.M....Capdeville R.	2018

Sources

Genes for Leukemia, Acute Myeloid

Genes related to Leukemia, Acute Myeloid (36 elite genes):

(show top 50) (show all 203)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CEBPA	CCAAT Enhancer Binding Protein Alpha	Protein Coding	1718.49	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative germline mutation ⁵⁹ Causative variation ⁷⁵ Genetic Tests ²⁹ Unconfirmed association ⁵⁷ DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)	11242107 20963938 22138009 (more) 23970018 12661007
2	GATA2	GATA Binding Protein 2	Protein Coding	1350.34	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative germline mutation ⁵⁹ Susceptibility factor ⁵⁷ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	21670465 20040766 21765025 (more) 21242295 21892162 20963938 22138009 23970018
3	FLT3	Fms Related Tyrosine Kinase 3	Protein Coding	1302	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative somatic mutation ⁵⁹ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	12384447 20963938 22138009 (more) 23970018 11290608 14670924 11442493
4	JAK2	Janus Kinase 2	Protein Coding	1206.85	Molecular basis known ⁵⁷ Pathogenic ⁶ Causative variation ⁷⁵ DISEASES inferred ¹⁵	20963938 22138009 23970018 (more) 16247455
5	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	1032.96	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
6	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1029.72	Molecular basis known ⁵⁷ Pathogenic ⁶ Genetic Tests ²⁹ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵	8955068 20963938 22138009 (more) 23970018
7	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	Protein Coding	950.59	Molecular basis known ⁵⁷ Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	7513208 9657776 20963938 (more) 22138009 23970018
	KIT::MIR221 ⁴⁷	MIR221 Macro RNA (hsa-miR-221) targets KIT
	KIT::MIR222 ⁴⁷	MIR222 Macro RNA (hsa-miR-222) targets KIT
8	NPM1	Nucleophosmin 1	Protein Coding	926.41	Molecular basis known ⁵⁷ Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	15659725 20963938 22138009 (more) 23970018
9	ETV6	ETS Variant 6	Protein Coding	906.48	Molecular basis known ⁵⁷ Pathogenic ⁶ DISEASES inferred ¹⁵	15806161 20963938 22138009 (more) 23970018
10	TGM6	Transglutaminase 6	Protein Coding	750	Pathogenic ⁶ Causative germline mutation ⁵⁹	20963938 22138009 23970018
11	TERT	Telomerase Reverse Transcriptase	Protein Coding	597.35	Molecular basis known ⁵⁷ Susceptibility factor ⁵⁷ Risk factor ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	19147845 20963938 22138009 (more) 23970018
12	CHIC2	Cysteine Rich Hydrophobic Domain 2	Protein Coding	553.34	Molecular basis known ⁵⁷ Susceptibility factor ⁵⁷ DISEASES inferred ¹⁵
13	RUNX1	Runt Related Transcription Factor 1	Protein Coding	526.9	Molecular basis known ⁵⁷ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
14	PICALM	Phosphatidylinositol Binding Clathrin Assembly Protein	Protein Coding	521.95	Molecular basis known ⁵⁷ DISEASES inferred ¹⁵ GeneCards inferred via : Summaries (show sections)
15	MLLT10	MLLT10, Histone Lysine Methyltransferase DOT1L Cofactor	Protein Coding	506.66	Molecular basis known ⁵⁷ DISEASES inferred ¹⁵
16	NUP214	Nucleoporin 214	Protein Coding	505.91	Molecular basis known ⁵⁷ DISEASES inferred ¹⁵
17	NSD3	Nuclear Receptor Binding SET Domain Protein 3	Protein Coding	504.3	Molecular basis known ⁵⁷ DISEASES inferred ¹⁵
18	LPP	LIM Domain Containing Preferred Translocation Partner In Lipoma	Protein Coding	500	Molecular basis known ⁵⁷
19	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	449.82	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)	20963938 22138009 23970018
20	IDH1	Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic	Protein Coding	432.65	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
21	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial	Protein Coding	432.65	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
22	TP53	Tumor Protein P53	Protein Coding	431.84	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
23	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	431.6	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
24	DDX41	DEAD-Box Helicase 41	Protein Coding	403.83	Pathogenic ⁶ DISEASES inferred ¹⁵	20963938 22138009 23970018
25	SF3B1	Splicing Factor 3b Subunit 1	Protein Coding	400	Pathogenic ⁶	20963938 22138009 23970018
26	KMT2A	Lysine Methyltransferase 2A	Protein Coding	374.82	Gene fusion ⁵⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
27	TET2	Tet Methylcytosine Dioxygenase 2	Protein Coding	358.35	Causative somatic mutation ⁵⁹ DISEASES inferred ¹⁵
28	MIR34B	MicroRNA 34b Here, microRNAs (miRNA), which act as negative regulators of gene expression principally through translational repression, are investigated for the mediation of high CREB protein levels. A series of miRNAs that target CREB were identified. Real-time quantitative PCR revealed that miR-34b was expressed significantly less in myeloid cell lines, previously known for high CREB protein levels. Exogenous miR-34b expression was induced, and results revealed a direct interaction with the CREB 3'-untranslated region, with the consequent reduction of the CREB protein levels in vitro. miR-34b restored expression caused cell cycle abnormalities, reduced anchorage-independent growth, and altered CREB target gene expression, suggesting its suppressor potential. Using reverse-phase protein array, CREB target proteins (BCL-2, cyclin A1, cyclin B1, cyclin D, nuclear factor-kappaB, Janus-activated kinase 1, and signal transducer and activator of transcription 3), as well as many downstream protein kinases and cell survival signaling pathways (AKT/mammalian target of rapamycin and extracellular signal-regulated kinase) usually elicited by CREB, were observed to have decreased. The miR-34b/miR-34c promoter was shown to be methylated in the leukemia cell lines used. This epigenetic regulation should control the observed miR-34b expression levels to maintain the CREB protein overexpressed. In addition, the inverse correlation between miR-34b and CREB expression was found in a cohort of 78 pediatric patients at diagnosis of acute myeloid leukemia, supporting this relationship in vivo. Our results identify a direct miR-34b target gene, provide a possible mechanism for CREB overexpression, and provide new information about myeloid transformation and therapeutic strategies.	RNA Gene	350	Causal ⁴⁷	19258499
29	MIR126	MicroRNA 126 Our gain- and loss-of-function experiments showed that miR-126/126* inhibited apoptosis and increased the viability of AML cells and enhanced the colony-forming ability of mouse normal bone marrow progenitor cells alone and particularly, in cooperation with AML1-ETO, likely through targeting Polo-like kinase 2 (PLK2), a tumor suppressor. A significantly negative effect on luciferase activity was observed in the presence of miR-126 on the 3 UTR of PLK2. These results indicate that PLK2 is a bona fide target of miR-126.	RNA Gene	350	Causal ⁴⁷	18832181
30	MIR320A	MicroRNA 320a we have identified a panel of TPA-induced miRNAs that are expressed coincident with HL-60 stereotypic morphological changes characteristic of monocytic differentiation. The transferrin receptor 1(TfR-1; CD71), whose surface expression is downregulated during TPA-mediated HL-60 cell differentiation, has been identified as a target of the TPA-induced miRNA miR-320. Cell culture experiments indicate that enforced miR-320 expression can suppress TfR-1 expression and cell proliferation. CONCLUSION: TPA induces the expression of several miRNAs in HL-60 cells, one such miRNA (miR-320) contributes to downregulation of TfR-1 surface expression characteristically seen during HL-60 monocytic differentiation. Moreover, TfR-1-targeting miRNAs, such as miR-320, may have potential as novel therapeutic agents for cancer due to their inhibitory effects on cell proliferation.	RNA Gene	350	Causal ⁴⁷	19135902
31	MIR204	MicroRNA 204 The authors confirmed that miR-204 targets HOXA10 and MEIS1, suggesting that the HOX upregulation observed inNPMc AMLmaybe due in part by loss ofHOX regulators-miRNAs.	RNA Gene	350	Causal ⁴⁷	18308931
32	SETBP1	SET Binding Protein 1	Protein Coding	304.62	Causative variation ⁷⁵ DISEASES inferred ¹⁵
33	IRAIN	IGF1R Antisense Imprinted Non-Protein Coding RNA We demonstrate that this lncRNA interacts with chromatin DNA and is involved in the formation of an intrachromosomal enhancer/promoter loop. In addition,IRAIN was downregulated both in leukemia cell lineand in blood obtained from high-risk AML patients. Activating the IGF1R gene,lead to growth advantage and tumor progression. Dysfunction Pattern: Regulation [down-regulated]	RNA Gene	154.36	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	25092925
34	HOTAIRM1	HOXA Transcript Antisense RNA, Myeloid-Specific 1 The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Dysfunction Pattern: Locus	RNA Gene	154.04	Experimental evidence: Locus ³⁹ DISEASES inferred ¹⁵	26436590
35	CCDC26	CCDC26 Long Non-Coding RNA We found that CCDC26 transcripts were abundant in the nuclear fraction of K562 human myeloid leukemia cells. We suggest that CCDC26 controls growth of myeloid leukemia cells through regulation of KIT expression.A KIT inhibitor might be an effective treatment against the forms of AML in which CCDC26 is altered. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	153.54	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵	25928165
36	WT1-AS	WT1 Antisense RNA The incidence of WIT-1 methylation in primary refractory AML was significantly higher than that noted in chemosensitive AML (P=0.018). Dysfunction Pattern: Expression [differentially expressed]	RNA Gene	153.33	Experimental evidence: Expression ³⁹ DISEASES inferred ¹⁵	10340388
37	CDKN2B-AS1	CDKN2B Antisense RNA 1 Altered expression of the antisense RNA related to p15/INK4B is observed in AML cell lineand leads to p15 silencing,whereas a coordinated regulation of ANRIL and p14/ARF,p16/INK4A,p15/INK4B transcription has been observed in both physiologic and pathologic conditions. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	21414664
38	UCA1	Urothelial Cancer Associated 1 In this study,we identified the oncogenic urothelial carcinoma associated 1 (UCA1) lncRNA as a novel target of the C/EBP?-p30.While wild-type C/EBP? represses,C/EBP?-p30 can induce UCA1 transcription.Notably,we also show that UCA1 expression increases in cytogenetically normal AML cases carrying biallelic CEBPA mutations.Thus,we identified,for the first time,an oncogenic lncRNA functioning in concert with the dominant negative isoform of C/EBP? in AML. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	26053097
39	CCAT1	Colon Cancer Associated Transcript 1 the aberrant upregulation of CCAT1 was detected in French-American-British M4 and M5 subtypes of adult AML patients. By gain- and loss-of-function analysis,we determined that CCAT1 repressed monocytic differentiation and promoted cell growth of HL-60 by sequestering tumor suppressive miR-155. Accordingly,a significant decrease in miR-155 level was detected in AML patients. Re-introduction of miR-155 into HL-60 cells restored monocytic maturation and repressed cell proliferation. Furthermore,CCAT1 could up-regulated c-Myc via its competing endogenous RNA (ceRNA) activity on miR-155. In conclusion,these results revealed new mechanism of lncRNA CCAT1 in AML development,and suggested that the manipulation of CCAT1 expression could serve as a potential strategy in AML therapy. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	26923190
40	MEG3	Maternally Expressed 3 MEG3 hypermethylation occurred in 15 MDS patients (34.9%),and in 20 AML patients (47.6%). SNRPN hypermethylation was observed in 15 MDS patients (34.9%),and in 21 AML patients (50%). There were no significant correlations between WHO subtype,WPSS score,karyotype,haemoglobin levels,white blood cell count,platelet count and CpG methylation of any gene. MEG3 hypermethylation was associated with significantly reduced overall survival in individuals with AML (HR=1.98,p=0.04),while SNRPN CpG methylation was not associated with survival (HR=0.94,p=0.87). Dysfunction Pattern: Regulation [down-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	19595458
41	TUG1	Taurine Up-Regulated 1 LncRNA TUG1 expression was higher in AML patients compared to controls and correlated with higher white blood cell counts, monosomal karyotype, FLT3-ITD mutation, poor-risk stratification, and poor prognosis, which independently predicted worse event-free survival and overall survival. In vitro, lncRNA TUG1 expression was higher in AML cell lines (KG-1, MOLM-14, HL-60, NB-4, and THP-1 cells) compared to controls. LncRNA TUG1 mimic promoted cell proliferation and decreased cell apoptosis rate, while lncRNA TUG1 inhibitor repressed cell proliferation and increased cell apoptosis rate. Rescue experiment showed that AURKA attenuated the influence of lncRNA TUG1 on AML cell proliferation and apoptosis. Dysfunction Pattern: Expression [high expression]	RNA Gene	150	Experimental evidence: Expression ³⁹	29654398
42	TUSC7	Tumor Suppressor Candidate 7 Overexpression of the LSAMP and TUSC7 genes in acute myeloid leukemia following microdeletion/duplication of chromosome 3. Dysfunction Pattern: Expression	RNA Gene	150	Experimental evidence: Expression ³⁹	26345353
43	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1 We found that MALAT-1 expression in patients with acute monocytic leukemia (M5) was significantly increased when compared with that of healthy controls, and the overall survival of M5 patients with high MALAT-1 expression was markedly reduced when compared with the overall survival of patients with low MALAT-1 expression. The analysis of cellular experiments showed that MALAT-1 silencing decreased the proliferation of M5 cells (U-937 and THP-1), inhibited cell cycle progression and increased apoptosis. Dysfunction Pattern: Expression [high expression]	RNA Gene	150	Experimental evidence: Expression ³⁹	28713913
44	HOTAIR	HOX Transcript Antisense RNA Overexpression of long non-coding RNA HOTAIR predicts a poor prognosis in patients with acute myeloid leukemia. Dysfunction Pattern: Expression	RNA Gene	150	Experimental evidence: Expression ³⁹	26622861
45	MLF1	Myeloid Leukemia Factor 1	Protein Coding	56.1	Genetic association ⁵⁷ DISEASES inferred ¹⁵
46	NSD1	Nuclear Receptor Binding SET Domain Protein 1	Protein Coding	55.8	Genetic association ⁵⁷ DISEASES inferred ¹⁵
47	SH3GL1	SH3 Domain Containing GRB2 Like 1, Endophilin A2	Protein Coding	54.66	Genetic association ⁵⁷ DISEASES inferred ¹⁵
48	CBFB	Core-Binding Factor Subunit Beta	Protein Coding	54.44	Genetic association ⁵⁷ DISEASES inferred ¹⁵
49	MIR424	MicroRNA 424 Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805
50	MIR451A	MicroRNA 451a Six (i.e., miR-128a,miR-128b, miR-151*, miR-5, miR-130b, and miR-210) were expressed at a significantly higher level in ALL than in AML. In contrast, the remaining 21 (i.e., let-7b, miR-223, let-7e, miR-125a, miR-130a, miR-221, miR-222, miR-23a, miR-23b, miR-24, miR-27a, miR-27b, let-7a,let-7c, miR-199b, miR-26a, miR-335, miR-21,miR-22, miR-424, and miR-451) were expressed at a significantly higher level in AML compared with ALL.	RNA Gene	50	Unspecified ⁴⁷	18056805

Sources

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

⁷⁵

#	Symbol	AA change	Variation ID	SNP ID
1	CEBPA	p.His84Leu	VAR_072677	rs28931590
2	JAK2	p.Lys607Asn	VAR_032696	rs121912472
3	JAK2	p.Val617Phe	VAR_032697	rs77375493
4	SETBP1	p.Gly870Ser	VAR_063809	rs267607040
5	SETBP1	p.Ser854Ala	VAR_069848
6	SETBP1	p.Gly870Arg	VAR_069854
7	SETBP1	p.Ile871Ser	VAR_069856

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

⁶

(show top 50) (show all 672)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	ETV6	NM_001987.4(ETV6): c.226G> T (p.Glu76Ter)	single nucleotide variant	Pathogenic	rs121434637	GRCh37	Chromosome 12, 11992136: 11992136
2	ETV6	NM_001987.4(ETV6): c.226G> T (p.Glu76Ter)	single nucleotide variant	Pathogenic	rs121434637	GRCh38	Chromosome 12, 11839202: 11839202
3	ETV6	NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly)	insertion	Pathogenic	rs587776710	GRCh37	Chromosome 12, 12043928: 12043929
4	ETV6	NM_001987.4(ETV6): c.1307_1308insGGG (p.His436delinsGlnGly)	insertion	Pathogenic	rs587776710	GRCh38	Chromosome 12, 11890994: 11890995
5	TP53	NM_000546.5(TP53): c.742C> T (p.Arg248Trp)	single nucleotide variant	Pathogenic	rs121912651	GRCh37	Chromosome 17, 7577539: 7577539
6	TP53	NM_000546.5(TP53): c.742C> T (p.Arg248Trp)	single nucleotide variant	Pathogenic	rs121912651	GRCh38	Chromosome 17, 7674221: 7674221
7	TP53	NM_000546.5(TP53): c.743G> A (p.Arg248Gln)	single nucleotide variant	Pathogenic/Likely pathogenic	rs11540652	GRCh37	Chromosome 17, 7577538: 7577538
8	TP53	NM_000546.5(TP53): c.743G> A (p.Arg248Gln)	single nucleotide variant	Pathogenic/Likely pathogenic	rs11540652	GRCh38	Chromosome 17, 7674220: 7674220
9	TP53	NM_000546.5(TP53): c.818G> A (p.Arg273His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28934576	GRCh37	Chromosome 17, 7577120: 7577120
10	TP53	NM_000546.5(TP53): c.818G> A (p.Arg273His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28934576	GRCh38	Chromosome 17, 7673802: 7673802
11	KRAS	NM_033360.3(KRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs112445441	GRCh37	Chromosome 12, 25398281: 25398281
12	KRAS	NM_033360.3(KRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs112445441	GRCh38	Chromosome 12, 25245347: 25245347
13	KRAS	NM_004985.4(KRAS): c.35G> A (p.Gly12Asp)	single nucleotide variant	Pathogenic	rs121913529	GRCh37	Chromosome 12, 25398284: 25398284
14	KRAS	NM_004985.4(KRAS): c.35G> A (p.Gly12Asp)	single nucleotide variant	Pathogenic	rs121913529	GRCh38	Chromosome 12, 25245350: 25245350
15	KRAS	NM_004985.4(KRAS): c.35G> T (p.Gly12Val)	single nucleotide variant	Pathogenic	rs121913529	GRCh37	Chromosome 12, 25398284: 25398284
16	KRAS	NM_004985.4(KRAS): c.35G> T (p.Gly12Val)	single nucleotide variant	Pathogenic	rs121913529	GRCh38	Chromosome 12, 25245350: 25245350
17	KRAS	NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly)	duplication	Pathogenic	rs606231202	GRCh38	Chromosome 12, 25245356: 25245358
18	KRAS	NM_004985.4(KRAS): c.27_29dupTGG (p.Gly10_Ala11insGly)	duplication	Pathogenic	rs606231202	GRCh37	Chromosome 12, 25398290: 25398292
19	HRAS	NM_005343.3(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
20	HRAS	NM_005343.3(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
21	HRAS	NM_005343.3(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh37	Chromosome 11, 534288: 534288
22	HRAS	NM_005343.3(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh38	Chromosome 11, 534288: 534288
23	HRAS	NM_005343.3(HRAS): c.436G> A (p.Ala146Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104894231	GRCh38	Chromosome 11, 533467: 533467
24	HRAS	NM_005343.3(HRAS): c.37G> T (p.Gly13Cys)	single nucleotide variant	Pathogenic	rs104894228	GRCh37	Chromosome 11, 534286: 534286
25	HRAS	NM_005343.3(HRAS): c.37G> T (p.Gly13Cys)	single nucleotide variant	Pathogenic	rs104894228	GRCh38	Chromosome 11, 534286: 534286
26	HRAS	NM_005343.3(HRAS): c.436G> A (p.Ala146Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104894231	GRCh37	Chromosome 11, 533467: 533467
27	HRAS	NM_005343.3(HRAS): c.437C> T (p.Ala146Val)	single nucleotide variant	Likely pathogenic	rs121917759	GRCh37	Chromosome 11, 533466: 533466
28	HRAS	NM_005343.3(HRAS): c.437C> T (p.Ala146Val)	single nucleotide variant	Likely pathogenic	rs121917759	GRCh38	Chromosome 11, 533466: 533466
29	HRAS	NM_005343.3(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
30	HRAS	NM_005343.3(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
31	KIT	NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913506	GRCh37	Chromosome 4, 55599320: 55599320
32	KIT	NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913506	GRCh38	Chromosome 4, 54733154: 54733154
33	KIT	NM_000222.2(KIT): c.2446G> C (p.Asp816His)	single nucleotide variant	Pathogenic	rs121913506	GRCh37	Chromosome 4, 55599320: 55599320
34	KIT	NM_000222.2(KIT): c.2446G> C (p.Asp816His)	single nucleotide variant	Pathogenic	rs121913506	GRCh38	Chromosome 4, 54733154: 54733154
35	NRAS	NM_002524.4(NRAS): c.37G> C (p.Gly13Arg)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434595	GRCh37	Chromosome 1, 115258745: 115258745
36	NRAS	NM_002524.4(NRAS): c.37G> C (p.Gly13Arg)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434595	GRCh38	Chromosome 1, 114716124: 114716124
37	NRAS	NM_002524.4(NRAS): c.182A> G (p.Gln61Arg)	single nucleotide variant	Pathogenic	rs11554290	GRCh37	Chromosome 1, 115256529: 115256529
38	NRAS	NM_002524.4(NRAS): c.182A> G (p.Gln61Arg)	single nucleotide variant	Pathogenic	rs11554290	GRCh38	Chromosome 1, 114713908: 114713908
39	NRAS	NM_002524.4(NRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs121434596	GRCh37	Chromosome 1, 115258744: 115258744
40	NRAS	NM_002524.4(NRAS): c.38G> A (p.Gly13Asp)	single nucleotide variant	Pathogenic	rs121434596	GRCh38	Chromosome 1, 114716123: 114716123
41	NPM1	NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs)	duplication	Pathogenic	rs587776806	GRCh38	Chromosome 5, 171410540: 171410543
42	NPM1	NM_002520.6(NPM1): c.860_863dupTCTG (p.Trp288Cysfs)	duplication	Pathogenic	rs587776806	GRCh37	Chromosome 5, 170837544: 170837547
43	NPM1	NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh38	Chromosome 5, 171410543: 171410544
44	NPM1	NM_002520.6(NPM1): c.863_864insCATG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh37	Chromosome 5, 170837547: 170837548
45	NPM1	NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh38	Chromosome 5, 171410543: 171410544
46	NPM1	NM_002520.6(NPM1): c.863_864insCGTG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh37	Chromosome 5, 170837547: 170837548
47	NPM1	NM_002520.6(NPM1): c.863_864insCCTG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh38	Chromosome 5, 171410543: 171410544
48	NPM1	NM_002520.6(NPM1): c.863_864insCCTG (p.Trp288Cysfs)	insertion	Pathogenic	rs587776806	GRCh37	Chromosome 5, 170837547: 170837548
49	JAK2	NM_004972.3(JAK2): c.1849G> T (p.Val617Phe)	single nucleotide variant	Pathogenic	rs77375493	GRCh37	Chromosome 9, 5073770: 5073770
50	JAK2	NM_004972.3(JAK2): c.1849G> T (p.Val617Phe)	single nucleotide variant	Pathogenic	rs77375493	GRCh38	Chromosome 9, 5073770: 5073770

Copy number variations for Leukemia, Acute Myeloid from CNVD:

⁷ (show top 50) (show all 491)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	13336	1	1	124300000	Insertion		Acute myeloid leukemia
2	13759	1	1	28000000	Deletion		Acute myeloid leukemia
3	14790	1	110122000	110569000	Gain or loss		Acute myeloid leukemia
4	17466	1	142902432	245422360	Duplication		Acute myeloid leukemia
5	18096	1	143961000	247125000	Gain or loss		Acute myeloid leukemia
6	20826	1	154656757	154656845	Amplification		Acute myeloid leukemia
7	24589	1	182359000	182787000	Loss		Acute myeloid leukemia
8	26098	1	197094625	197094734	Amplification		Acute myeloid leukemia
9	26100	1	197094796	197094905	Amplification		Acute myeloid leukemia
10	27148	1	204981000	205049000	Gain or loss		Acute myeloid leukemia
11	27263	1	206041820	206041907	Amplification		Acute myeloid leukemia
12	27859	1	214500000	224100000	Deletion		Acute myeloid leukemia
13	28491	1	222606000	222909000	Gain or loss		Acute myeloid leukemia
14	29341	1	230606000	230646000	Gain or loss		Acute myeloid leukemia
15	32943	1	40683565	40683656	Amplification		Acute myeloid leukemia
16	32944	1	40686494	40686582	Amplification		Acute myeloid leukemia
17	33084	1	42072000	42456000	Gain or loss		Acute myeloid leukemia
18	35033	1	5913000	7696000	Gain or loss		Acute myeloid leukemia
19	35608	1	65296705	65296779	Amplification		Acute myeloid leukemia
20	35769	1	67074000	69951000	Gain or loss		Acute myeloid leukemia
21	36085	1	71305902	71305987	Amplification	miR-186	Acute myeloid leukemia
22	38187	10	1	6700000	Insertion	IL15RA	Acute myeloid leukemia
23	38188	10	1	6700000	Insertion	PRKCQ	Acute myeloid leukemia
24	38677	10	104186259	104186331	Deletion		Acute myeloid leukemia
25	38804	10	105144000	105144148	Deletion		Acute myeloid leukemia
26	39144	10	110889374	110889450	Deletion		Acute myeloid leukemia
27	39902	10	122017230	122017301	Deletion	let-7a-2	Acute myeloid leukemia
28	41668	10	21893278	22027081	Loss	MLLT10	Acute myeloid leukemia
29	41990	10	27075530	27189965	Translate	SSH3BP1	Acute myeloid leukemia
30	43278	10	46100000	49900000	Copy number	GDF10	Acute myeloid leukemia
31	44445	10	57165247	57165335	Deletion		Acute myeloid leukemia
32	44874	11	64658609	64658718	Deletion	miR-192	Acute myeloid leukemia
33	45369	10	70521000	135283000	Gain		Acute myeloid leukemia
34	47681	10	96486000	100815000	Loss		Acute myeloid leukemia
35	49592	11	108316750	133951370	Triplication		Acute myeloid leukemia
36	50142	11	114500000	121200000	Copy number	MLL	Acute myeloid leukemia
37	50190	11	115400000	120700000	Insertion	DDX6	Acute myeloid leukemia
38	50191	11	115400000	120700000	Insertion	ETS1	Acute myeloid leukemia
39	50192	11	115400000	120700000	Insertion	FLI1	Acute myeloid leukemia
40	50193	11	115400000	120700000	Insertion	MLL	Acute myeloid leukemia
41	50261	11	116297361	116448564	Loss		Acute myeloid leukemia
42	50346	11	117203762	118563610	Amplification		Acute myeloid leukemia
43	50385	11	117603158	117860329	Duplication		Acute myeloid leukemia
44	50437	11	117820656	117856311	Gain	MLL	Acute myeloid leukemia
45	50640	11	118585028	127052111	Deletion		Acute myeloid leukemia
46	51468	11	126537000	130235000	Gain		Acute myeloid leukemia
47	51512	11	127394408	133951311	Amplification		Acute myeloid leukemia
48	52810	11	2016406	2019065	Methylation	H19	Acute myeloid leukemia
49	53744	11	32409321	32457081	Mutation	WT1	Acute myeloid leukemia
50	54217	11	39671000	39746000	Loss		Acute myeloid leukemia

Sources

Expression for Leukemia, Acute Myeloid

Search GEO for disease gene expression data for Leukemia, Acute Myeloid.

Sources

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

³⁷

#	Name	Kegg Source Accession
1	Acute myeloid leukemia	hsa05221
2	Transcriptional misregulation in cancer	hsa05202

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

(show all 17)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.74	FLT3 JAK2 KIT KRAS NRAS TERT
2	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.54	CEBPA FLT3 KIT KRAS NRAS RUNX1
3	NF-kappaB Signaling ⁴	12.28	CEBPA GATA2 JAK2 KIT RUNX1
4	Pathways in cancer ³⁷	12.28	CEBPA FLT3 JAK2 KIT KRAS NRAS
5	CNTF Signaling ⁶⁴ Show member pathways BDNF Pathway ⁶⁴ FLT3 Signaling ⁶⁴ IL-3 Pathway ⁶⁴ Nur77-Induced AICD in Macrophage ⁶⁴ OSM Pathway ⁶⁴	12.26	FLT3 JAK2 KRAS NRAS
6	Transcriptional misregulation in cancer ³⁷	12.03	CEBPA ETV6 FLT3 RUNX1
7	Tyrosine Kinases / Adaptors ⁴	11.88	FLT3 JAK2 KIT NPM1
8	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.78	JAK2 KRAS NRAS
9	AGE-RAGE signaling pathway in diabetic complications ³⁷	11.73	JAK2 KRAS NRAS
10	C-MYB transcription factor network ¹	11.58	CEBPA KIT NRAS
11	HIF-1-alpha transcription factor network ¹	11.48	GATA2 NPM1 TERT
12	Negative regulation of MAPK pathway ⁶⁶ Show member pathways RAF activation ⁶⁶	11.47	JAK2 KRAS NRAS
13	VEGF Pathway (Tocris) ⁷² Show member pathways Sorafenib Pharmacodynamics ⁶¹	11.38	FLT3 KIT KRAS NRAS
14	Transcription_Transcription factor Tubby signaling pathways ²²	11.14	JAK2 KRAS NRAS
15	Central carbon metabolism in cancer ³⁷	10.83	FLT3 IDH1 KIT KRAS NRAS
16	Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex ¹	10.78	DNMT3A ETV6 FLT3
17	p38MAPK events ⁶⁶	10.64	KRAS NRAS

Sources

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	9.85	CEBPA DNMT3A GATA2 JAK2 MLLT10 NPM1
2	nucleus	GO:0005634	9.8	CEBPA DNMT3A ETV6 FLT3 GATA2 JAK2
3	focal adhesion	GO:0005925	9.02	JAK2 KRAS LPP NPM1 NUP214

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of cell proliferation	GO:0008284	9.83	FLT3 JAK2 KIT KRAS NPM1
2	MAPK cascade	GO:0000165	9.76	JAK2 KIT KRAS NRAS
3	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.54	FLT3 JAK2 KIT
4	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.5	FLT3 JAK2 KIT
5	positive regulation of MAP kinase activity	GO:0043406	9.43	FLT3 KIT KRAS
6	hematopoietic stem cell proliferation	GO:0071425	9.4	ETV6 RUNX1
7	cytokine-mediated signaling pathway	GO:0019221	9.35	CEBPA FLT3 JAK2 KIT KRAS
8	myeloid progenitor cell differentiation	GO:0002318	9.16	FLT3 KIT
9	hemopoiesis	GO:0030097	9.02	FLT3 GATA2 KIT PICALM RUNX1

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein binding	GO:0005515	9.58	CEBPA CHIC2 DNMT3A ETV6 FLT3 GATA2
2	protein homodimerization activity	GO:0042803	9.43	CEBPA FLT3 IDH1 KIT NPM1 TERT

Sources

Sources for Leukemia, Acute Myeloid

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia

Leukemia, Acute Myeloid

Aliases & Classifications for Leukemia, Acute Myeloid

MalaCards integrated aliases for Leukemia, Acute Myeloid:

Characteristics:

Orphanet epidemiological data:

OMIM:

HPO:

Classifications:

External Ids:

Summaries for Leukemia, Acute Myeloid

Related Diseases for Leukemia, Acute Myeloid

Diseases in the Myeloid Leukemia family:

Diseases related to Leukemia, Acute Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Leukemia, Acute Myeloid:

Symptoms & Phenotypes for Leukemia, Acute Myeloid

Symptoms via clinical synopsis from OMIM:

Clinical features from OMIM:

Human phenotypes related to Leukemia, Acute Myeloid:

UMLS symptoms related to Leukemia, Acute Myeloid:

GenomeRNAi Phenotypes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Leukemia, Acute Myeloid:

Drugs & Therapeutics for Leukemia, Acute Myeloid

FDA approved drugs:

Drugs for Leukemia, Acute Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 73 / NDF-RT 51 :

Cell-based therapeutics:

Cochrane evidence based reviews: leukemia, myeloid, acute

Genetic Tests for Leukemia, Acute Myeloid

Genetic tests related to Leukemia, Acute Myeloid:

Anatomical Context for Leukemia, Acute Myeloid

MalaCards organs/tissues related to Leukemia, Acute Myeloid:

Publications for Leukemia, Acute Myeloid

Articles related to Leukemia, Acute Myeloid:

Genes for Leukemia, Acute Myeloid

Genes related to Leukemia, Acute Myeloid (36 elite genes):

Variations for Leukemia, Acute Myeloid

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Myeloid:

ClinVar genetic disease variations for Leukemia, Acute Myeloid:

Copy number variations for Leukemia, Acute Myeloid from CNVD:

Expression for Leukemia, Acute Myeloid

Pathways for Leukemia, Acute Myeloid

Pathways related to Leukemia, Acute Myeloid according to KEGG:

Pathways related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

GO Terms for Leukemia, Acute Myeloid

Cellular components related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Biological processes related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Molecular functions related to Leukemia, Acute Myeloid according to GeneCards Suite gene sharing:

Sources for Leukemia, Acute Myeloid

Inferred drug relations via UMLS ⁷³ / NDF-RT ⁵¹ :